Background: Allergic rhinitis (AR) is an inflammatory disease mediated by immunoglobulin E (IgE) following exposure of the nasal mucosa to an allergen. Glycophosphopeptical (GFP) is a molecule composed of polysaccharides of fungal origin and proteins of vegetal origin, adsorbed in an inorganic phosphate-sulfate-calcium matrix, stimulates the innate immunity, during infectious processes. Objective: The objective of the study was to analyze the clinical response of specific immunotherapy (SIT) and the use of GFP in patients with allergic rhinitis. Methods: An observational, retrospective, comparative and analytical study was carried out, with non-probabilistic sampling of consecutive cases. We reviewed records of patients diagnosed with allergic rhinitis treated at least 6 months with GFP and SIT. Descriptive statistics, Student's t and Wilcoxon's test were used for comparation. Results: The total group was 22 (36.6%) men and 38 (63.3%) women, with a mean age of 31 years (4-58), the group with SIT 9 (30%) men and 21 (70%) women; The SIT + GFP group with 13 (43.3%) men and 17 (56.6%) women. The two groups presented clinical improvement, related to the number of infections and improvement of symptoms. When comparing both groups (SIT vs. SIT + GFP) after treatment, there were no statistically significant differences related to the number of infections (P < 0.061) and no significant differences between the change in the ARIA score in the group with SIT (P = 0.536) and SIT + GFP (P = 0.619). Conclusion: GFP added to SIT does not produce superior clinical improvement in patients with allergic rhinitis compared to SIT alone.